

III Itun

Annual Results 2022 Webcast presentation

Stijn Van Rompay, CEO Jean-Luc Vandebroek, CFO

Forward-Looking Statements

This presentation has been prepared by, and is the sole responsibility of, Hyloris Pharmaceuticals SA (the "Company") for discussions with investors in relation to the Company and its group. For the purposes of this notice, "presentation" means this document, oral presentation, any question and answer session and any written or oral material discussed or distributed during the presentation meetings. This presentation (or any part of it) may not be reproduced or redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person (whether inside or outside such person's organization or firm) or published for any purpose or under any circumstances.

This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for, any securities of the Company in any jurisdiction and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This presentation does not contain all the information that a prospective purchaser of securities of the Company may desire or require in deciding whether or not to purchase such securities nor does it constitute a due diligence review and should not be construed as such. This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident in any jurisdiction where such distribution or use would be contrary to law or regulation or would require any registration or licensing within such jurisdiction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Any person into whose possession this presentation comes should inform themselves about, and observe, any such restrictions.

This presentation includes market, economic and industry data, which were obtained by the Company from scientific journals, industry publications, press releases, data published by government agencies, industry reports prepared by consultants and other market data providers. While the information has been accurately reproduced, and in as far as the Company is aware and is able to ascertain from such third-party information, no facts have been omitted which would render the reproduction of this third-party information inaccurate or misleading, the Company cannot guarantee its accuracy or completeness. Accordingly, you should not place reliance on any of the market, economic and industry data contained in this presentation.

This presentation includes statements that are, or may be deemed to be, "forward-looking statements" which are based on current expectations and projections about future events. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, these forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. A number of factors could cause actual results or outcomes to differ materially from those expressed, projected or implied in any forward-looking statements. In light of these risks, uncertainties and assumptions, the events or circumstances referred to in the forward-looking statements may not occur. None of the future projections, expectations, estimates or prospects in the materials should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the materials. No one undertakes to publicly update or revise any such forward-looking statement, whether as a result of new information, future events or otherwise. As a result of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual results or otherwise.

By attending and otherwise accessing this presentation you will be deemed to have read and understood the contents of this disclaimer. In making an investment decision, you must rely on your own assessment, examination, analysis and enquiry of the Company.



Agenda for Today's Call

- New product candidates
- Commercial milestones
- Pipeline expansion
- **Financial position**
- Expected milestones (12 months)
- Q&A

Patented Value-Added Medicines: Pharma's Sweet Spot

New indications, combinations, reformulations

Unique Features

Patented value-added 505(b)(2) medicines: Optimised existing medicines


Efficacy, safety, new use, compliance, onset of action, drug titration, convenience

Key Benefits to Patients, Physicians and Payors New Chemical Entities & Biologicals

Off-patent ethical compounds and generics

Risk, Cost and Timelines

Pipeline expansion: ~30 Assets before 2025



Addressable market

Market size	7% of population
Absolute numbers	~ 19 million patients in the US ~ 25,8 million patients in Europe
Seeks specialist treatment	13% of the above, following ~8 years of trial and error

HY-083

Nasal Administration

Indication: Idiopathic rhinitis (chronic rhinitis without a known cause) Unmet medical need: providing first reliable treatment

Symptoms: Runny nose, stuffy nose, sneezing fits without a medical diagnosis (allergies, infection, inflammation, ...)

- Impacting **quality of life** daily (sleep patterns, drowsiness, irritability, poor concentration)
- Molecule with known mechanism of action: block TRPV1 receptor in the nose
- Both rapid and sustainable relief



Pipeline expansion: ~30 Assets before 2025



Addressable market

Market Size

5% of hospitalized patients*

HY-088 – January 2023 Oral liquid

Indication: **Phosphate deficiency (hypophosphatemia)** *Unmet medical need:* No approved treatment exists today

- Phosphate deficiency is mostly asymptomatic
- Severe condition can be **life threatening** (respiratory or heart failure)
- Rich body of clinical data of widely used but unapproved treatment
- Always linked to **underlying condition**
- Condition affects 5%* of hospitalized patients
- **Direct treatment** for subpopulation during and/or after hospital stay



Value-added portfolio, commercialized with partners

Product	Route of Adminstration	Indication	Formulation & Manufacturing	Clinical Development	Regulatory Filling	Target Marke	t
Maxigesic® IV	Intravenous	Post-operative pain	License	ed in >100 countries		GLOBAL AFT	harmaceutici 🌍
Tranexamic Acid	Oral Mouth Rinse	(Dental) bleeding				GLOBAL	6
Miconazole - DB	Topical	Recurring VVC				GLOBAL	§
Alenura	Instillation	IC/BPS				GLOBAL	
Plecoid Agent IV	Intravenous	AML and SCLC				GLOBAL	
Atomoxetine	Oral Liquid	ADHD				USA	۲
HY-029	Oral Liquid	Viral Infection				USA	۲
HY-083	Nasal Spray	Idiopathic Rhinitis				GLOBAL	6
HY-088	Oral Liquid	Hypophosphatemia				GLOBAL	§
	and Fusidic Ac	er generic products, TXA I id Cream have not been i intravenous ; RTU: ready to use	ncluded in the above overview	TXA: tranexamic acid ADHD: attention deficit hyp Miconazole-DB: miconazole rVVC: recurring vulvovagina AML: Acute Myeloid Leuke SCLC: Small cell Lung Cance	e-domiphen bromide al candidiasis mia		

Broad, innovative cardiovascular portfolio

Product	Route of Adminstration	Indication	Formulation & Manufacturing	Clinical Development	Regulatory Filling	Target Market	
Sotalol IV	Intravenous	Atrial fibrillation	U	lp to 7 years			
Aspirin IV	Intravenous	Acute coronary syndrome				GLOBAL	S
Milrinone	Extended-release capsule	Advanced heart failure (LVAD)				GLOBAL	
Dofetilide IV	Intravenous	Atrial fibrillation				USA	
Metolazone IV	Intravenous	Congestive heart failure				USA	۲
HY-074	Intravenous	Acute coronary syndrome				GLOBAL	
HY-075	Oral Liquid	Coronary heart disease				USA	۲
Inte	ended to be commercialised by Hyl	oris in the U.S.					

Intended to be commercialised with partner


LVAD: battery-operated, mechanical surgically implanted pump, which helps the left ventricle of the heart pump blood



• Our high barrier generic products, TXA RTU, HY-016

and Fusidic Acid Cream have not been included in the above overview

Pipeline expansion: ~30 Assets before 2025





Maxigesic IV: Significant Growth of Commercial Footprint



Commercial roll-out:

- Out-licensing agreement in 9 additional European countries, registration completed in 5
- Additional licenses and approvals worldwide

UTICALS

- United States: NDA submission expected in H1, implying potential market approval in H2
- 4 U.S. patents granted to Hyloris, expiry between 2035 and 2039

10

Commercial highlights

Sotalol IV

 Further commercial efforts to accelerate commercial roll-out in the United States

Tranexamic Acid RTU

- Out-licensing agreements
 - 1 European country
 - 1 Southeast Asian country
- Combined population of 60 million
- Ex-US potential exceeds internal expectations

HY-038

- €1 million out-licensing fee of non-core generic asset
- Increased focus on value-added repurposed candidates

Commercial progress Focus on value-added product candidates Strategic out-license agreements



Financial Highlights 2022

(in € thousand)	2022	2021	% change
Revenue	2,951	3,096	-4.7%
Cost of sales	-94	-107	/
R&D	(10,151)	(5,056)	100.8%
G&A	(3,517)	(2,900)	21.3%
Other (income/expenses)	173	(5,573)	/
Operating Result	-10,638	-10,541	0.9%
Result of the period	-10,770	-11,579	-7.0%
Cash and cash equivalents	43,457	50,012	-13.1%

Key Factors

• Revenues:

- Increased royalties in 2022 contribute more to current topline
- Out-licensing fee of €1 million (HY-038)
- 2021 revenue impacted by upfront milestone payment (€1.8 million) (Maxigesic IV)


• Operating expenses:

- Higher R&D expenses, following portfolio expansion
- Headcount grew from 21 (YE 2021) to 39 today

12



Financial position 31 December 2022



• Net cash burn of €6.5 million in 2022 - Cash position end of 2022 amounted to €43.5 million.

 Assuming additional out-licensing, commercial success of Maxigesic and Sotalol IV, additional non-dilutive funding and milestones payments, the Company is sufficiently capitalized to execute full development of its current pipeline assets(16+3)

Anticipated Value Inflection Milestones in the next 12 months

Clinical

- Alenura[™] starting multiple trials, among which four-arm phase 2 clinical trial
- Miconazole/DB: Phase 2 top line results in H1 2023
- Starting Phase 3 clinical trial on HY004 (Tranexamic Acid Oral Mouth Rinse)
- HY-029 and Dofetilide IV: start pivotal PK studies

Regulatory

- Maxigesic[®] IV in the U.S.
 Submission before summer 2023
- Potential NDA approval before end of 2023
- Global market authorizations for Maxigesic[®] IV

Commercial

Commercial partnership(s)

- Out-licensing deal(s)
- In-licensing deal(s)

Ambition to expand the product portfolio to ~30 assets before 2025







investorrelations@hyloris.com